s
s
s
Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug vedolizumab (Entyvio) using ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Vedolizumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Vedolizumab Inhibitory Type 1 |
HCA292 |
AbD30136 |
Fab-FH1 |
0.1 |
PK bridging ELISA |
|
HCA293 |
AbD30136_hIgG1 |
Human IgG1 |
0.1 |
ADA control |
||
HCA294 |
AbD30138_hIgG1 |
Human IgG1 HRP |
1.5 |
PK bridging ELISA ADA control |
||
HCA295 |
AbD30139_hIgG1 |
Human IgG1 |
4 |
ADA control |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-vedolizumab antibodies inhibit the binding of the drug vedolizumab to its target, human lymphocyte alpha4-beta7-integrin. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Fig. 1. Vedolizumab PK bridging ELISA using antibodies HCA292 and HCA294P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Vedolizumab ADA bridging ELISA using antibody HCA293, HCA294 or HCA295.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.